#1 Clinical Trials Search in Europe

Domvanalimab

Domvanalimab is an innovative immunotherapy drug currently being investigated in several clinical trials for the treatment of various types of cancer. This article provides an overview of ongoing research into domvanalimab’s potential as a cancer treatment, either alone or in combination with other immunotherapy agents. The trials aim to evaluate its safety, efficacy, and optimal use in different cancer types and stages.

Table of Contents

What is Domvanalimab?

Domvanalimab (also known as AB154) is a new type of cancer drug called an immunotherapy. It is a humanized monoclonal antibody, which means it’s a lab-made protein designed to target a specific part of the immune system[1]. Domvanalimab is still being studied in clinical trials and is not yet approved for general use by regulatory agencies like the FDA.

How Does Domvanalimab Work?

Domvanalimab works by targeting a protein called TIGIT (T cell immunoreceptor with Ig and ITIM domains) that is found on certain immune cells. TIGIT acts as a “brake” on the immune system. By blocking TIGIT, domvanalimab aims to “release the brakes” and help the immune system fight cancer more effectively[2].

What Cancers is Domvanalimab Being Studied For?

Domvanalimab is being investigated for several types of cancer, including:

  • Non-small cell lung cancer (NSCLC): This is the most common type of lung cancer[1][3]
  • Hepatobiliary cancers: These include cancers of the liver and bile ducts[4]
  • Melanoma: A type of skin cancer[5]
  • Bladder cancer: Specifically, muscle-invasive bladder cancer[6]
  • Gastric and gastroesophageal junction cancers: Cancers of the stomach and where the stomach meets the esophagus[7]

How is Domvanalimab Given?

Domvanalimab is given as an intravenous (IV) infusion, which means it’s delivered directly into the bloodstream through a vein. In most studies, it’s given every 3 weeks (also called Q3W). The exact dose can vary, but one common dose being studied is 1200 mg every 3 weeks[4][6].

Domvanalimab in Combination Therapies

Many clinical trials are studying domvanalimab in combination with other cancer drugs. Some common combinations include:

  • Domvanalimab + Zimberelimab: Zimberelimab (also known as AB122) is another immunotherapy drug that targets a protein called PD-1[1]
  • Domvanalimab + Zimberelimab + Etrumadenant: Etrumadenant (also known as AB928) is a drug that targets proteins called A2aR and A2bR[8]
  • Domvanalimab + Durvalumab: Durvalumab is another immunotherapy drug[3]

These combinations are being studied because researchers believe they may work better together than any single drug alone.

Potential Side Effects

As domvanalimab is still in clinical trials, all of its potential side effects are not yet known. However, common side effects of immunotherapy drugs can include:

  • Fatigue
  • Skin rashes
  • Diarrhea
  • Nausea
  • Fever

More serious side effects can occur if the immune system attacks healthy parts of the body. Researchers are carefully monitoring patients in clinical trials for any adverse events[2].

Ongoing Clinical Trials

There are several ongoing clinical trials studying domvanalimab. These trials are looking at how well the drug works, how safe it is, and how it affects the body (pharmacokinetics). Some trials are also collecting samples to study biomarkers, which are biological indicators that might help predict who will respond best to the treatment[1][7].

If you’re interested in participating in a clinical trial for domvanalimab, talk to your oncologist. They can help you understand if you might be eligible for any ongoing trials and what participation would involve.

Aspect Details
Drug Name Domvanalimab (AB154)
Drug Type Humanized immunoglobulin G1 (IgG1) monoclonal antibody
Target TIGIT (T cell Immunoreceptor with Ig and ITIM domains)
Cancer Types Studied Non-small cell lung cancer, melanoma, glioblastoma, hepatobiliary cancers, rare cancers
Administration Intravenous (IV) infusion
Common Combinations Zimberelimab (anti-PD-1), Etrumadenant (A2aR and A2bR antagonist)
Primary Outcomes Measured Safety, tolerability, progression-free survival, overall survival, objective response rate
Trial Phases Phase 0/I, Phase II, Phase III
Current Status Investigational, not yet approved for general use

FAQ

  • What is domvanalimab? Domvanalimab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets the immune checkpoint TIGIT. It is designed to enhance the body's immune response against cancer cells.
  • What types of cancer are being studied with domvanalimab? Clinical trials are investigating domvanalimab for various cancer types, including non-small cell lung cancer, melanoma, glioblastoma, hepatobiliary cancers, and rare cancers such as peritoneal mesothelioma and gestational trophoblastic tumors.
  • How is domvanalimab administered? Domvanalimab is typically administered as an intravenous (IV) infusion. The dosage and frequency may vary depending on the specific trial and combination therapy being studied.
  • What are the potential side effects of domvanalimab? As with any immunotherapy, domvanalimab may cause side effects. The clinical trials are designed to assess its safety profile and monitor for adverse events. Common side effects of immunotherapies can include fatigue, skin reactions, and immune-related events.
  • Is domvanalimab approved for use outside of clinical trials? Currently, domvanalimab is still in the investigational stage and is not approved for general use outside of clinical trials. Its safety and efficacy are being evaluated through these studies to determine its potential for future approval and broader use in cancer treatment.

Ongoing Clinical Trials on Domvanalimab

  • Study on Durvalumab and Domvanalimab for Patients with Stage III Unresectable Non-Small Cell Lung Cancer After Chemoradiation Therapy

    Recruiting

    1 1 1
    Investigated drugs:
    Belgium France Germany Greece Hungary Italy +4

  • Study of Sacituzumab Govitecan for Patients with Advanced or Metastatic Bladder Cancer

    Recruiting

    1 1 1
    Investigated drugs:
    France Germany Greece Italy Spain

  • A study of irinotecan, fluorouracil, calcium folinate, zimberelimab, and domvanalimab for patients with metastatic gastro-enteropancreatic neuroendocrine carcinoma.

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Safety and Effectiveness of Domvanalimab and Zimberelimab for Adults with Advanced Rare Cancers Resistant to Standard Treatment

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • A study testing zimberelimab, domvanalimab, and sacituzumab govitecan for patients with PD-L1 positive advanced triple-negative breast cancer

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study of FOLFIRI with Domvanalimab and Zimberelimab in patients with advanced gastric or gastro-esophageal junction cancer who progressed after chemotherapy

    Not recruiting

    1 1 1
    Investigated drugs:
    France

  • Study of Domvanalimab and Zimberelimab Combined with Chemotherapy for Previously Untreated Recurrent or Metastatic Head and Neck Cancer

    Not recruiting

    1 1 1
    Investigated drugs:
    France Italy Spain

  • Study on the Safety and Effectiveness of Domvanalimab, Zimberelimab, and Quemliclustat in Adults with Advanced Upper Gastrointestinal Cancer

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study Comparing Zimberelimab and Domvanalimab with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Untreated Metastatic Non-Small Cell Lung Cancer

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium France Germany Italy The Netherlands +2

  • Study of Domvanalimab, Zimberelimab, and Chemotherapy for Patients with Advanced Esophageal or Gastric Cancer

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Greece Hungary Italy Lithuania Poland +3

Glossary

  • TIGIT: T cell Immunoreceptor with Ig and ITIM domains, an immune checkpoint protein targeted by domvanalimab to enhance the immune system's ability to fight cancer.
  • PD-1: Programmed Death-1, another immune checkpoint protein often targeted in combination with TIGIT in cancer immunotherapy.
  • Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. Used in cancer treatment and diagnosis.
  • Immunotherapy: A type of cancer treatment that helps the immune system fight cancer. Domvanalimab is an example of an immunotherapy drug.
  • Clinical trial: A research study that tests how well new medical approaches work in people, such as new ways to prevent, detect, diagnose, or treat diseases like cancer.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with cancer without the disease getting worse.
  • Overall survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Objective response rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Adverse event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Combination therapy: The use of more than one medication or treatment simultaneously to treat a condition or disease.

References

  1. https://clinicaltrials.gov/study/NCT04262856
  2. https://clinicaltrials.gov/study/NCT03628677
  3. https://clinicaltrials.eu/trial/study-on-durvalumab-and-domvanalimab-for-patients-with-stage-iii-unresectable-non-small-cell-lung-cancer-after-chemoradiation-therapy/
  4. https://clinicaltrials.gov/study/NCT05724563
  5. https://clinicaltrials.gov/study/NCT05130177
  6. https://clinicaltrials.gov/study/NCT06133517
  7. https://clinicaltrials.gov/study/NCT06250036
  8. https://clinicaltrials.gov/study/NCT04791839